Fig. 6

In vivo antitumor effect and in vivo toxicity. A The therapeutic schedule. B Tumor growth curves in each group at given time points. C Average tumor weights in each group in the end. D Representative images of CT26 tumor tissues in the end. E Immunohistochemical staining of Ki67 in tumor tissues. F Western blot analysis of CD44 and STAT1 in CT26 tumor-bearing mice after treatment. G Immunohistochemical staining of CD44 in CT26 tumor tissues. H Body weight change curves. I–K Liver function markers (ALT, AST, and ALP) and kidney function markers (BUN and CRE) after different treatments